Details of the Drug Reposition | DrugMAP

General Information of This Drug (ID: DM5Z8ID)

Drug Name	Tabelecleucel DM5Z8ID
Synonyms	Tab-cel
Drug Type	Cell therapy

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)

1 Phase 3 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Post-transplant lymphoproliferative disorder	DISTS43D	2B32	Phase 3	[1]
------------------------------------------------------------------------------------

1 Phase 2 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Nasopharyngeal carcinoma	DISAOTQ0	2B6B	Phase 2	[2]
------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT03394365) Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) After Failure of Rituximab or Rituximab and Chemotherapy (ALLELE). U.S. National Institutes of Health.
2	ClinicalTrials.gov (NCT00953420) Carboplatin and Docetaxel Followed by Epstein-Barr Virus Cytotoxic T Lymphocytes (CADEN). U.S. National Institutes of Health.